Suppr超能文献

联合分析血浆代谢组和肠道微生物组测序以探索加参方及其在改变肠-心轴方面的潜在作用以及对慢性心力衰竭的影响。

Combined analysis of plasma metabolome and intestinal microbiome sequencing to explore jiashen prescription and its potential role in changing intestine-heart axis and effect on chronic heart failure.

作者信息

Cui Xialian, Su Yangyan, Huang Xiaotong, Chen Jiaping, Ma Jiang, Liao Peiran, He Xin

机构信息

School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.

Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou, China.

出版信息

Front Cardiovasc Med. 2023 Mar 10;10:1147438. doi: 10.3389/fcvm.2023.1147438. eCollection 2023.

Abstract

BACKGROUND

Heart failure (HF) is a syndrome with global clinical and socioeconomic burden worldwide owing to its poor prognosis. Jiashen Prescription (JSP), a traditional Chinese medicine (TCM) formula, exhibits unambiguous effects on treating HF. Previously, we have reported that underlying mechanisms of JSP by an untargeted metabolomics approach, but the contribution of gut microbiota and metabolic interaction to the cardioprotective efficacy of JSP remains to be elucidated.

MATERIALS AND METHODS

Firstly, the rat model of heart failure was established by the permanent ligation of the left anterior descending coronary artery. The efficacy evaluation of JSP in treating HF rats was per-formed by left ventricular ejection fraction (LVEF). Then, 16S rRNA gene sequencing and LC/MS-based metabolomic analysis were utilized to explore the characteristics of cecal-contents microecology and plasma metabolic profile, respectively. After that, the correlation between intestinal micro-ecological characteristics and plasma metabolic characteristics was analyzed to explore the potential mechanism of the JSP treatment in HF.

RESULTS

JSP could improve the cardiac function of heart failure rats and thus ameliorate heart failure enhancing rat LVEF. Results of intestinal flora analysis revealed that JSP not only adjusted gut microbiota disturbances by enriching species diversity, reducing the abundance of pathogenic bacteria (such as ), as well as increasing the abundance of beneficial bacteria (such as ), but also improved metabolic disorders by reversing metabolite plasma levels to normality. Through the conjoint analysis of 8 metabolites and the OTUs relative abundance data in the 16srRNA sequencing results by WGCNA method, 215 floras significantly related to the eight compounds were identified. The results of the correlation analysis demonstrated a significant association between intestinal microbiota and plasma metabolic profile, especially the significant correlation of and Protoporphyrin IX, and nicotinamide, dihydrofolic acid.

CONCLUSION

The present study illustrated the underlying mechanism of JSP to treat heart failure by affecting intestinal flora and plasma metabolites, provide a potential therapeutic strategy against heart failure.

摘要

背景

心力衰竭(HF)是一种全球范围内具有临床和社会经济负担的综合征,因其预后较差。加参方(JSP)是一种中药配方,在治疗HF方面具有明确疗效。此前,我们已通过非靶向代谢组学方法报道了JSP的潜在机制,但肠道微生物群和代谢相互作用对JSP心脏保护作用的贡献仍有待阐明。

材料与方法

首先,通过永久性结扎左冠状动脉前降支建立大鼠心力衰竭模型。通过左心室射血分数(LVEF)对JSP治疗HF大鼠的疗效进行评估。然后,分别利用16S rRNA基因测序和基于LC/MS的代谢组学分析来探究盲肠内容物微生态特征和血浆代谢谱。之后,分析肠道微生态特征与血浆代谢特征之间的相关性,以探究JSP治疗HF的潜在机制。

结果

JSP可改善心力衰竭大鼠的心功能,从而通过提高大鼠LVEF来改善心力衰竭。肠道菌群分析结果显示,JSP不仅通过丰富物种多样性、降低病原菌(如 )丰度以及增加有益菌(如 )丰度来调节肠道微生物群紊乱,还通过将代谢物血浆水平恢复正常来改善代谢紊乱。通过WGCNA方法对16srRNA测序结果中的8种代谢物和OTU相对丰度数据进行联合分析,鉴定出与这8种化合物显著相关的215种菌群。相关性分析结果表明肠道微生物群与血浆代谢谱之间存在显著关联,尤其是 与原卟啉IX、 与烟酰胺、二氢叶酸之间的显著相关性。

结论

本研究阐明了JSP通过影响肠道菌群和血浆代谢物来治疗心力衰竭的潜在机制,为心力衰竭提供了一种潜在的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55eb/10036802/a09d56b01b1b/fcvm-10-1147438-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验